As the effects of life choices accumulate, the liver can enter a pathway to Non-Alcoholic Fatty Liver Disease (NAFLD) leading to an endpoint of liver cirrhosis (NASH). Frequent monitoring of the fatty liver markers becomes a measure of life choices. Type 2 diabetes, for example, can be reversed by monitoring fatty liver markers and changing lifestyle.
This panel provides an opportunity for clinics to develop lifestyle and diabetes programmes for diseases with an global cost estimated to reach $2.5 trillion by 2030. Diabetes alone already affects 4.7m British and 30m Americans, with 70% of these suffering fatty liver disease.
